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Mesenchymal Stem Cells Prevent Hypertrophic
Scar Formation via Inflammatory Regulation when
Undergoing Apoptosis
Shiyu Liu1,2,5, Lan Jiang1,3,5, Haijian Li1,3, Haigang Shi1, Hailang Luo1,4, Yongjie Zhang1,4, Chunyan Yu3 and
Yan Jin1,2
The cutaneous wound-healing process can lead to hypertrophic scar formation, during which exaggerated
inflammation has been demonstrated to have an important role. Therefore, an exploration of strategies designed
to regulate this inflammatory process is warranted. Mesenchymal stem cells (MSCs) have recently been
demonstrated to regulate inflammation in various diseases. In this regard, using a rabbit model, we locally
injected human mesenchymal stem cells (hMSCs) derived from bone marrow to treat hypertrophic scar
formation, and explored their underlying mechanisms. We found that hMSC therapy efficiently regulated
inflammation and prevented scar formation. We attributed the therapeutic effects of hMSCs to their secretion of
an anti-inflammatory protein, TNF-alpha-stimulated gene/protein 6 (TSG-6). Unexpectedly, after injection, the
number of surviving hMSCs decreased markedly and the hMSCs underwent extensive apoptosis, which was
demonstrated to promote their secretion of TSG-6, partially through the activation of caspase-3. Moreover, H2O2-
induced apoptotic hMSCs showed higher inflammatory regulatory abilities. The inhibition of caspase-3
decreased the inflammatory regulatory abilities of hMSCs and attenuated their therapeutic effects. Our results
demonstrate that hMSCs can efficiently prevent hypertrophic scar formation via inflammatory regulation. In
addition, we found that apoptosis has an important role in the activation of the inflammatory regulatory abilities
of hMSCs.
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INTRODUCTION
Errors in cutaneous wound healing can result in excessive
healing, leading to the formation of hypertrophic scars
(Gurtner et al., 2008). Scar formation during healing, instead
of normal regeneration, leads to adverse consequences
including loss of functions, restriction of movements, poor
aesthetics, and adverse psychological effects, placing a burden
on public health (Ferguson and O’Kane, 2004; Aarabi et al.,
2007). Although the definitive mechanisms of scar formation
remain to be elucidated, an important role that exaggerated
inflammation has in this process is well recognized (Gurtner
et al., 2008; van der Veer et al., 2009).
In adult cutaneous wound healing, inflammatory cells are
recruited to the wound and produce proinflammatory media-
tors such as monocyte chemotactic protein-1 (MCP-1), macro-
phage inflammatory protein-1 beta (MIP-1b), interleukin-1
beta (IL-1b), and interleukin-6 (IL-6). These mediators can
not only induce additional inflammation but also contribute
to excess extracellular matrix (ECM) deposition and fibrosis
(Smith et al., 1998; Ferreira et al., 2006; Gieling et al., 2009;
van der Veer et al., 2009). Moreover, the inflamma-
tory cells can produce growth factors such as transforming
growth factor-beta 1 (TGF-b1) and platelet-derived growth
factor, which stimulate fibroblast proliferation, myofibroblast
differentiation, and excess ECM deposition, leading to scar
formation (Satish and Kathju, 2010). In comparison with
wound healing in adults, wounds in early mammalian
embryos heal perfectly without scar formation (Larson et al.,
2010). Previous studies have shown that embryonic wounds
have the following: (1) fewer inflammatory cells, (2) a reduced
length of time that inflammatory cells are present, and (3)
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lower levels of inflammatory factors. (Ferguson and O’Kane,
2004; Satish and Kathju, 2010). Similarly, the oral mucosa
wound-healing process shows markedly reduced scar forma-
tion, compared with cutaneous wound healing, including
reduced inflammatory cell infiltration and proinflammatory
factor production (Szpaderska et al., 2003; Larson et al.,
2010). The literature regarding the cellular and molecular
differences in inflammation between scar-free wound healing
and scar-forming wound healing indicates that scar formation
may be prevented by inflammatory regulation. It was pre-
viously shown that overexpression of interleukin-10 (IL-10), an
anti-inflammatory cytokine, decreased inflammatory responses
and prevented scar formation (Peranteau et al., 2008).
Recently, mesenchymal stem cells (MSCs) have been
demonstrated to be important guardian cells for inflammatory
regulation (Prockop and Oh, 2012). The administration of
MSCs has been shown to regulate excessive inflammation and
generate therapeutic effects in animal models for a number of
inflammation-related diseases, including lung injury (Ortiz
et al., 2007), sepsis (Nemeth et al., 2009), myocardial infarc-
tion (Lee et al., 2009), sterile injury to the cornea (Roddy et al.,
2011), and stroke (Mora-Lee et al., 2012). Our previous
studies have demonstrated that MSCs derived from adipose
tissue enhance skin wound healing (Liu et al., 2011) and
prevent vocal fold scar formation (Liang et al., 2012). Taken
together, these studies suggest that MSCs may regulate
inflammation during cutaneous wound healing and prevent
hypertrophic scar formation. Compared with non-cell-based
therapies aimed at inflammatory regulation, therapies using
MSCs have several advantages. The therapeutic effects of
MSCs are explained by their activation of inflammatory
signals, which stimulate them to secrete anti-inflammatory
factors. Indeed, it is thought they can generate inflammatory
regulatory effects in multiple ways that are responsive to
different inflammatory microenvironments (Prockop and Oh,
2012). The various inflammatory modulators secreted by
MSCs include the following: nitric oxide (NO), indoleamine
2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), IL-10, and
TNF-alpha-stimulated gene/protein 6 (TSG-6) (Le Blanc and
Mougiakakos, 2012; Shi et al., 2012). These multiple factors
make MSCs superior to other therapies that only focus on one
factor, because single factors may not be sufficient to prevent
scar formation (van der Veer et al., 2009).
Although MSCs have been successfully applied for many
kinds of diseases, the underlying mechanisms have not been
fully elucidated. Interestingly, in most experimental situations,
MSCs generate therapeutic effects without evidence of long-
term engraftment, and most of the cells are dead and cleared
in a short time after administration (Lee et al., 2009; Roddy
et al., 2011). Accordingly, their beneficial effects are
explained by paracrine secretions or cell-to-cell contacts that
have multiple effects including regulation of inflammation or
immune reactions (Le Blanc and Mougiakakos, 2012);
however, whether MSCs generate therapeutic effects when
they are dying, especially undergoing apoptosis, has not been
investigated. As such, in the current study, we tried to use
human mesenchymal stem cells (hMSCs) derived from bone
marrow to prevent the formation of hypertrophic scars in a
rabbit model. The aim of this study was to investigate whether
the application of hMSCs could provide a strategy for treating
hypertrophic scar formation and to evaluate whether the
hMSCs generated these therapeutic effects while they were
undergoing apoptosis.
RESULTS
Local injection of hMSCs efficiently prevented hypertrophic scar
formation
The hMSCs used in this study were positive for mesenchymal
surface markers (Supplementary Figure S1a online) and had
multidifferentiation potentials toward osteoblasts and adipo-
cytes (Supplementary Figure S1b and c online). In a rabbit ear
hypertrophic scar model, local injection of hMSCs efficiently
prevented scar formation and decreased the outstanding
height on postoperative day 28 (Figure 1a and b). At the same
time, histological analysis revealed that hMSC treatment
reduced the thickness of granulation tissues on postoperative
day 14 and prevented scar formation on postoperative day 28
(Figure 1c). Moreover, scar elevation index, which was used to
quantitatively evaluate scar formation (Kloeters et al., 2007),
was significantly reduced in the hMSC-treated group
(Figure 1d). Further evaluation of collagen deposition in the
wound area was indicated by Masson’s trichrome staining.
The results showed that, similar to normal unwounded tissue
(Supplementary Figure S2b online), the hMSC-treated group
had less collagen deposition, lighter staining (Figure 1e), and
lower integrated optical density (Figure 1f), compared with the
control group. Moreover, as indicated by real-time PCR assay,
the expressions of collagen type I a1 (ColIa1) and alpha-
smooth muscle actin (a-SMA) were significantly downregu-
lated in the hMSC-treated group (Figure 1g and h). In this
study, we also isolated rabbit mesenchymal stem cells (rMSCs)
from bone marrow, which had multidifferentiation potentials
toward osteoblasts and adipocytes (Supplementary Figures S3a
and b online). Similarly, we found that local injection of
rMSCs efficiently prevented scar formation and decreased the
outstanding height on postoperative day 28 (Supplementary
Figure S3c and d online). Taken together, these results indicate
that local injection of hMSCs efficiently prevented hyper-
trophic scar formation.
hMSCs regulated inflammation and prevented scar formation
partially through TSG-6
MSCs have been demonstrated to modulate inflammation
through the secretion of multiple factors, such as TSG-6,
NO, IDO, PGE2, and IL-10 (Le Blanc and Mougiakakos, 2012;
Shi et al., 2012). In this study, the expression levels of TSG-6,
inducible nitric oxide synthase, IDO, cyclooxygenase 2 (an
inducible enzyme involved in PGE2 biosynthesis), and IL-10
in hMSCs were evaluated using real-time PCR assay with
primers specific to human genes. Our results showed that the
expressions of all these genes in hMSCs increased after local
injection, with the level of TSG-6 showing the largest change
(Figure 2a). As such, we next evaluated whether TSG-6 had an
essential role in inflammatory regulation by hMSCs. TSG-6
gene expression was knocked down by small interfering RNA
(siRNA) (Supplementary Figure S4a and b online). We found
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that local injection of hMSCs prevented CD45- and CD3-
positive cells infiltration in the wound area, which was
attenuated by TSG-6 knockdown in hMSCs by siRNA
(Figure 2b and c). Moreover, the expression levels of proin-
flammatory/profibrotic mediators, including MCP-1, MIP-1b,
IL-1b, IL-6, and TGF-b1 (Figure 2d–h), were all downregulated
after hMSC-based treatment. Knockdown of TSG-6 expression
in hMSCs significantly attenuated the inhibitory effects on
MCP-1, MIP-1b, IL-6, and TGF-b1. Finally, knockdown
of TSG-6 attenuated the therapeutic effects of hMSCs
on scar formation (Figure 2i and j). Similarly, local injec-
tion of rMSCs prevented CD45- and CD3-positive cells
infiltration in the wound area (Supplementary Figure S5a
and b online) and downregulated the expression levels of
proinflammatory/profibrotic mediators (Supplementary Figure
S5c–f online). In summary, these results indicate that the
secretion of TSG-6 by hMSCs has an important role in their
therapeutic effects.
hMSCs underwent extensive apoptosis and survived for a short
time after injection
At 24 and 72 hours post injection, surviving hMSCs could be
detected around the wound area (Figure 3a). To quantitatively
evaluate the percentage of the surviving hMSCs, we used the
species differences between the rabbit model and the hMSCs
to detect human-specific glyceraldehyde-3-phosphate dehy-
drogenase gene expression by real-time PCR, as described
previously (Lee et al., 2009). The standard curve generated by
this experiment was linear (Figure 3b), with the sensitivity to
detect 10 hMSCs in one rabbit-wound area tissue, which
amounted to 0.002% of injected cells. Further analysis
showed that the number of hMSCs decreased immediately
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Figure 1. Local injection of human mesenchymal stem cells (hMSCs) prevented hypertrophic scar formation in a rabbit scar model. (a) Images of wounds
created on rabbit ear and the scar formation on postoperative day 28. Scale bar¼ 5 mm. (b) The analysis of the outstanding height of the scar on postoperative
day 28 (n¼ 12). (c) Hematoxylin and eosin (H&E) staining of wound area tissues on postoperative days 14 and 28. Bar¼ 2 mm. The double arrows indicate the
granulation tissues on postoperative day 14. The dotted lines indicate the wound edges. (d) The analysis of scar elevation index (SEI) based on H&E staining on
postoperative day 28 (n¼ 6). (e) Masson’s trichrome staining of wound area tissues followed by integrated optical density (IOD) analysis (f) on postoperative
day 28 (n¼ 12). Bar¼ 200mm. (g, h) Real-time PCR assay of collagen type I a1 (ColIal) and alpha-smooth muscle actin (a-SMA) expressions in wound
area on postoperative day 7 (n¼3). Values are means±SD. **Po0.01.
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and markedly after injection, and their number became very
low at 7 days post injection (Figure 3c). Given the large
decrease of hMSCs, we evaluated whether they were under-
going apoptosis. TUNEL staining (Figure 3d) showed that the
hMSCs became apoptotic after injection, and the percentage
of TUNEL-positive hMSCs reached a peak at 24 hours post
hMSC injection (Figure 3d and e). These data indicate that
hMSCs underwent extensive apoptosis after injection. Simi-
larly, we found that the rMSCs underwent extensive apoptosis
at 24 hours post injection (Supplementary Figure S6 online). At
the same time, the expression levels of caspase-3, -7, and -9 in
injected hMSCs were all upregulated after injection and
reached a peak at 24 hours post injection (Figure 3f). These
results demonstrate that the injected hMSCs underwent exten-
sive apoptosis and were quickly cleared from the wound site.
Apoptotic hMSCs increased TSG-6 expression partially through
caspase-3 activation
To evaluate whether there was a relationship between the
apoptosis of hMSCs and their therapeutic effects, a model of
cell apoptosis was established in vitro. The H2O2 treatment
significantly increased the percentage of TUNEL-positive cells
(Figure 4a) and induced caspase-3 activity (Figure 4b), which
were both attenuated by Z-DEVD-FMK, an inhibitor of
caspase-3. Interestingly, H2O2 treatment also increased the
expression of TSG-6, and pretreatment with Z-DEVD-FMK
attenuated this effect (Figure 4c). The TSG-6 expression
was then confirmed by ELISA (Figure 4d). In addition, we
found that the H2O2 treatment induced caspase-3 activity
(Supplementary Figure S7a online) and increased the expres-
sion of TSG-6 (Supplementary Figure S7b online) in rMSCs,
which were both attenuated by Z-DEVD-FMK. Taken together,
these results demonstrate that hMSCs promote the secretion of
TSG-6 when undergoing apoptosis.
Apoptosis partially governs the therapeutic effects of hMSCs on
hypertrophic scar formation
To evaluate the role of apoptosis in the therapeutic effects of
hMSCs on hypertrophic scar formation, untreated hMSCs, H2O2-
treated hMSCs (apoptotic hMSCs), and Z-DEVD-FMK-treated
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Figure 2. Human mesenchymal stem cells (hMSCs) regulated inflammation and prevented scar formation partially through TNF-alpha-stimulated
gene/protein 6 (TSG-6). (a) Human genome-specific real-time PCR assay of TSG-6, inducible nitric oxide synthase (iNOS), indoleamine 2,3-dioxygenase (IDO),
cyclooxygenase 2 (COX-2), and interleukin-10 (IL-10) levels in hMSCs at different time points post hMSC injection (n¼ 3). (b) Local injection of hMSC prevented
CD45-positive cell (red) and CD3-positive cell (green) infiltration on postoperative day 3 and day 5, respectively, which was attenuated by TSG-6 knockdown in
hMSCs by small interfering RNA (siRNA). Bar¼ 50mm. (c) The CD45- and CD3-positive cells were analyzed as the percentage of total detected cells (n¼ 12).
(d–h) Proinflammatory/profibrotic mediators in the wound area were analyzed by real-time PCR assay (d–f) (n¼ 3) or ELISA (g, h) (n¼ 6) on postoperative day 3.
(i) Images of wounds created on rabbit ear and the scar formation on postoperative day 28. Scale bar¼ 5 mm. (j) The analysis of the outstanding height of the
scar on postoperative day 28 (n¼ 12). Values are means±SD. **Po0.01.
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hMSCs were applied to the rabbit scar model, respectively.
At 24 hours post injection, the H2O2-treated hMSCs
showed the highest percentage of TUNEL-positive staining;
in contrast, Z-DEVD-FMK-treated hMSCs showed the lowest
percentage of TUNEL-positive cells (Figure 5a and b). In
accordance with these results, only a small number of
H2O2-treated hMSCs could be detected at 3 days post
injection, and these cells were totally undetectable at 5 days
post injection, thus showing a shorter survival time and full
clearance compared with untreated hMSCs and Z-DEVD-
FMK-treated hMSCs (Figure 5c). Moreover, H2O2-treated
hMSCs had higher inflammatory regulatory ability than
untreated hMSCs and Z-DEVD-FMK-treated hMSCs, which
was reflected by the expressions of MCP-1, MIP-1b, IL-6, and
TGF-b1 in the wound area (Figure 5d–g). Z-DEVD-FMK
treatment partially attenuated the inhibitory effects of hMSCs
on the expressions of these mediators (Figure 5d–g). The
higher inflammatory regulatory ability may be because of
the fact that the H2O2-treated hMSCs had a higher expression
level of TSG-6 after injection (Figure 5h). Finally, in accor-
dance with their inflammatory regulatory ability, H2O2-treated
hMSCs efficiently inhibited scar formation (Figure 5i and j).
In contrast, treatment of Z-DEVD-FMK attenuated the ther-
apeutic effects of hMSCs (Figure 5i and j). In summary, these
results demonstrate that the apoptosis of hMSCs has an
important role in their inflammatory regulatory abilities and
therapeutic effects on hypertrophic scar formation.
DISCUSSION
In the current study, our results demonstrated that local
injection of hMSCs efficiently prevented hypertrophic scar
formation by regulating inflammation. In addition, we found
that hMSC apoptosis has an important role in activating the
inflammatory regulatory abilities of hMSCs. Therefore, our
study not only provides a therapeutic strategy for hypertrophic
scar formation but also elucidates the molecular mechanisms
underlying this cell-based therapy.
Wound healing in the fetus does not produce scarring,
which has been attributed to a decreased ability to produce
proinflammatory mediators, or a shift in balance from proin-
flammatory to anti-inflammatory mediators (Peranteau et al.,
2008). The importance of regulating inflammation in fetal
wound healing suggests that a therapeutic strategy based on
inflammatory regulation could be beneficial in mature
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cutaneous wounds. Here, we found that hMSCs could regulate
inflammation during wound healing, which was in agreement
with previous studies showing that MSCs regulate
inflammation in different disease models (Prockop and Oh,
2012). It is well established that MSCs could regulate
inflammation through paracrine secretion (Prockop and Oh,
2012). In our study, hMSCs had increased expression levels of
several inflammatory regulatory factors, including TSG-6, NO,
IDO, PGE2, and IL-10, after injection into the wound area,
indicating that the wound microenvironment may provide
some signals that activate the inflammatory regulatory
potentials of hMSCs. These signals may include inflamma-
tory factors such as IFN-g and tumor necrosis factor-alpha,
which were previously shown to activate the inflammatory
regulatory potential of MSCs (Shi et al., 2012).
It is reported that TSG-6, a glycoprotein that was shown to
produce anti-inflammatory effects (Getting et al., 2002; Milner
et al., 2006; Choi et al., 2011), has an important role in MSC-
based inflammatory regulations and therapeutic effects (Lee
et al., 2009; Roddy et al., 2011). In our study, we found that
TSG-6 secretion by hMSCs has an important role in the
therapeutic effects on scar formation. This may be because
of the fact that hMSC-derived TSG-6 decreased the expression
levels of MCP-1 and MIP-1b, which were shown to induce
additional inflammation and contribute to excess ECM
deposition and fibrosis (Smith et al., 1998; Ferreira et al.,
2006; Gieling et al., 2009; van der Veer et al., 2009).
Moreover, we found that hMSC-derived TSG-6 decreased
the expression levels of IL-6 and TGF-b1, which were
shown to stimulate fibroblast proliferation, myofibroblast
differentiation, and excess ECM deposition (Satish and
Kathju, 2010). Previous studies found that MSC-derived TSG-
6 could attenuate the proinflammatory signals from macro-
phages (Choi et al., 2011), inhibit macrophage activation, and
reduce fibrosis in wound healing (Qi et al., 2014). Taken
together, we believe that in the wound-healing process,
hMSC-based therapy regulates inflammation partially through
TSG-6 secretion, mimicking a low inflammatory and scarless
wound healing microenvironment of the fetus.
Numerous studies have described the therapeutic effects of
MSCs in various diseases, including tissue repair and inflam-
mation/immunity regulation (Uccelli et al., 2008; Caplan,
2009). These therapeutic effects were initially explained by
long-term engraftment of MSCs, which differentiated into
multiple cell lineages in some experimental situations
(Liechty et al., 2000; Altman et al., 2008); however, thera-
peutic effects were more frequently observed without long-
term engraftment, in which paracrine secretions or cell-to-cell
contacts were demonstrated to have an important role (Lee
et al., 2009; Akiyama et al., 2012). Although the fact that
MSCs are quickly cleared after administration is well
established, the fate of these cells has not been fully eluci-
dated. In the current study, we found that the cell number of
hMSCs decreased markedly after their injection, and that
hMSCs underwent extensive apoptosis. Reasons for the
apoptosis of injected hMSCs include loss of matrix adhesion
and the effects of inflammatory cytokines (Reinecke et al.,
1999). Here, we speculated that the extensive and rapid
apoptosis of injected hMSCs may be related to their thera-
peutic effects. The function of apoptosis has been established
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in many biological contexts, including their role in clearance
of damaged and potent cancerous cells (Elmore, 2007).
Increasing evidence indicates that apoptosis could also
generate beneficial effects in regeneration (Bergmann and
Steller, 2010). Interestingly, we found that the secretion of
TSG-6 by hMSCs and their therapeutic effects were partially
governed by apoptosis. These findings unexpectedly indicate
that apoptosis not only leads to the clearance of infused
hMSCs but also has an important role in the activation of their
inflammatory regulatory abilities. Therefore, for the time being
we have shown a link between MSC apoptosis and their
therapeutic effects.
During the course of research into developing effective stem
cell-based therapies, some researchers tried to genetically
modify stem cells to increase their therapeutic potentials
(Kirkton and Bursac, 2008). However, these approaches
have been criticized for the potential risk associated with
the use of viral vectors (Walther and Stein, 2000). At the same
time, pretreatment with inflammatory factors such as IFN-g
(Polchert et al., 2008), IL-1b (Fan et al., 2012), or a hypoxic
environment (Rosova et al., 2008) could also promote the
therapeutic benefits of stem cells, suggesting some relatively
safer approaches. In the present study, we found that
pretreatment of hMSCs with H2O2 promoted their inflamma-
tory regulatory abilities, suggesting an approach to enhance
hMSC functions through inducible apoptosis. This result
requires further examination because although pretreated
hMSCs lead to scars with lower outstanding heights this was
not significantly different from untreated hMSCs. This may be
because of the fact that other factors except inflammation are
also involved in hypertrophic scar formation (van der Veer
et al., 2009).
Although stem cell-based therapy has been shown to be
effective in treating many kinds of diseases, there are potential
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risks including in vitro expansion, damage of normal organs,
and malignant transformation (Herberts et al., 2011). It is
thought that these risks could be reduced if it is possible to
quickly eliminate infused cells once their therapeutic effects
have been generated (Di Stasi et al., 2011). For e.g., some
approaches incorporated a ‘‘suicide’’ gene in the cells, which
induced efficient cell death at a certain time after admini-
stration (Tiberghien et al., 1994; Bonini et al., 1997). In the
current study, although the number of surviving cells
decreased markedly after injection, there existed a low
number of cells remaining in the wound area at 7 days post
injection. In contrast, pretreated hMSCs induced to become
apoptotic before injection were undetectable at 5 days post
injection; this approach efficiently boosted complete cell
clearance while still providing therapeutic effects. This
approach could be considered as a safe strategy for the
administration of cell-based therapy.
In this study, the hMSCs were used as xenografts in a rabbit
model based on several reasons. MSCs have been demon-
strated to be hypoimmunogenic (Ryan et al., 2005) and to be
able to inhibit immune response through soluble molecule
production (English et al., 2010) and cell–cell interactions with
immune cells (Akiyama et al., 2012). These properties enable
hMSCs to avoid immunological rejection when served as
allografts (Ren et al., 2012) and xenografts in mice (Lee et al.,
2009), rats (Jung et al., 2011), and rabbits (Niemeyer et al.,
2010). Moreover, the use of human cells in a rabbit model
enabled us to further evaluate the hMSC behaviors in vivo.
We made use of the species differences and performed
real-time PCR assay to evaluate the expressions of human
genes in vivo using human-specific primers. Finally, hMSCs
have been successfully applied to a variety of disease
therapies in clinical trials (Ren et al., 2012). Recently, Osiris
Therapeutics (Columbia, MD) was authorized to market the
first undifferentiated stem cell product, Prochymal, an
intravenously administered formulation of MSCs derived
from human bone marrow, for the treatment of acute graft-
versus-host disease (Prasad et al., 2011). This event showed a
promising prospect for clinical application of hMSCs. Thus,
the use of human cells in this study provides valuable
evidence for clinical applications of hMSCs in the future. To
evaluate whether the immune response of the host to the
xenografts affected the results in this study, we also used
rMSCs in the scar model. We found that, compared with the
hMSCs, the rMSCs generated similar therapeutic effects on
scar formation, showing similar apoptosis behavior and
inflammatory regulatory abilities. Thus, in this study, the
immune response of the host to the xenografts did not affect
the therapeutic effects of hMSCs on inflammation and scar
formation.
MATERIALS AND METHODS
Culture of hMSCs and rMSCs
The use of human samples was approved by the ethical committee of
the Fourth Military Medical University (Xi’an, China). hMSCs were
purified from heparinized bone marrow samples of adult donors (age
24–30) and cultured as previously described in our laboratory (Tang
et al., 2011). Briefly, the mononuclear cells were obtained by ficoll
density gradient centrifugation, suspended in regular culture medium
consisting of DMEM (Invitrogen, Carlsbad, CA) supplemented with
10% fetal bovine serum, 0.292 mg ml 1 glutamine, 100 U ml 1
penicillin G, 100mg ml 1 streptomycin (all from Invitrogen), and
seeded in 75-cm2 culture flasks (Costar, Cambridge, MA) at a density
of 1 105 cells ml 1. Cells at passages 3 and 4 were used for all the
experiments. The rMSCs were cultured as previously described
(Huang et al., 2004; Boo et al., 2011). Briefly, bone marrow was
extracted from tibias and femurs of New Zealand white female rabbits
weighting 2.8–3.0 kg. The mononuclear cells were then obtained and
cultured with the methods used for hMSCs. Cells at passages 3 and 4
were used for all the experiments.
Knockdown of TSG-6 by siRNA
Knockdown of TSG-6 by siRNA is described in the Supplementary
Materials and Methods online.
Apoptosis model in vitro
Apoptosis model in vitro is described in the Supplementary Materials
and Methods online.
Animal models and MSC-based treatment
All animal experiments were conducted in accordance with the
committee guidelines of the Fourth Military Medical University for
animal experiments, which, in turn, meet the NIH guidelines for the
care and use of laboratory animals. The New Zealand white female
rabbits weighting 2.8–3.0 kg used in this study were obtained from the
Experimental Animal Center of the Fourth Military Medical Univer-
sity. The hypertrophic scar models were established as previously
described (Kloeters et al., 2007). Briefly, the rabbits were anesthetized
by intramuscular administration of 5% pelltobarbitalum natricum
(25 mg kg 1) and Sumianxin (0.1 ml kg 1) and prepared for
wounding. Four wounds were created down to the bare cartilage
on the ventral side of each ear using a 7-mm dermal biopsy punch.
Cartilage damage needed to be avoided when the wounds were
created. Before treatment, the hMSCs and rMSCs were labeled with
DiO cell-labeling solution (Invitrogen) according to the manu-
facturer’s instructions. For treatments, 5 105 cells were suspended
in 80ml of phosphate-buffered saline and were intradermally injected
around each wound. phosphate-buffered saline (80ml) without cells
was used as control. Rabbits were randomly divided into six groups
(six animals in each group): Control, untreated hMSCs, untreated
rMSCs, hMSCs treated with siRNA, H2O2, or Z-DEVD-FMK.
Histological analysis
Animals were euthanized at 14 days and 28 days after the wounds
were created. Full-thickness biopsies of the wound-repair bed and
surrounding tissue were obtained. The maximum protuberant heights
of hypertrophic scars in rabbits were measured using calipers, as
previously described (Li et al., 2011). Paraffin sections were
subsequently stained with Masson’s trichrome or hematoxylin and
eosin. In each section of Masson’s trichrome staining, three high-
power fields in the dermis of wound area or unwounded normal
tissue, inferiorly by the ear cartilage and superiorly by the epithelial
basement membrane, were randomly selected and photographed.
The integrated optical density analysis of Masson’s trichrome staining
was performed by Image-Pro Plus 6.0 software (Media Cybernetics,
Silver Springs, MD), as previously described (Liang et al., 2012).
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The analysis of the scar elevation index, which was used to evaluate
the scar formation quantitatively in the rabbit scar model (Kloeters
et al., 2007), was performed using Image-Pro Plus 6.0 software.
Briefly, scar elevation index is the ratio of the total dermal area,
including the hypertrophied dermis and underlying dermis area, to
the area of the underlying dermis (Supplementary Figure S2a online).
The height of the underlying dermis is determined based on the height
of the adjacent unwounded dermis.
Immunofluorescence staining
Immunofluorescence staining is described in the Supplementary
Materials and Methods online.
TUNEL staining
TUNEL staining is described in the Supplementary Materials and
Methods online.
Real-time PCR assay
Real-time PCR assay is described in the Supplementary Materials and
Methods online.
Real-time PCR-based standard curve for human-specific GAPDH
Standard curve for human-specific GAPDH is described in the
Supplementary Materials and Methods online.
ELISA
ELISA is described in the Supplementary Materials and Methods
online.
Statistical analysis
Analysis was performed using the Statistical Program for Social
Science for Windows. Analysis of variance followed by Student’s
t-test was used to determine the significant differences between
groups. Comparisons of multiple groups were performed with analysis
of variance with corrections for multiple comparisons. P-valueo0.05
was considered statistically significant.
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